Voting Rights

Ardana PLC
28 February 2008

                                   Ardana plc
                           VOTING RIGHTS AND CAPITAL



Edinburgh, UK, February 28, 2008: Ardana plc (LSE:ARA), in conformity with the
Transparency Directive's transitional provision 6, today notifies the market of
the following:


As at 28 February 2008, the issued share capital and voting rights of Ardana plc
are as follows:


Ardana plc's capital consists of 65,511,729 ordinary 1p shares with voting
rights attached of one vote per ordinary share of which 12,681 ordinary shares
are held in Treasury.


Therefore, the total number of voting rights in Ardana plc is 65,499,048.


The above figure (65,499,048) may be used by shareholders as the denominator for
the calculations by which they will determine if they are required to notify
their interest in, or a change to their interest in, Ardana plc under the FSA's
Disclosure and Transparency Rules.




For more information contact:

Ardana plc                                              Financial Dynamics
Dr. Huw Jones. Chief Executive Officer                  Julia Phillips
Tel: + 44 (0) 131 226 8550                              Emma Thompson
                                                        Tel: [phone]



Ardana plc (LSE: ARA) is an emerging pharmaceutical company focused on the
discovery, development and marketing of innovative products to improve human
reproductive health, a $25.5 billion market.

Ardana's lead products are summarised below:



  • Teverelix LA, in development for three initial indications (prostate
    cancer, benign prostatic hyperplasia and endometriosis);
  • ARD-0705 a growth hormone secretagogue in Phase III for the diagnosis of
    growth hormone deficiency in adults;
  • Testosterone Cream, a transdermal testosterone delivery system in
    development for the treatment of male hypogonadism, in Phase III trials;
  • Emselex(R), a once a day treatment for the symptoms of overactive bladder
    syndrome, which Ardana has exclusive UK marketing and promotion rights and
    is being distributed in collaboration with Novartis UK Limited;
  • StriantTM SR, a testosterone replacement therapy that has been launched by
    Ardana through its own sales force in the UK and through marketing partners
    in certain European countries, as a treatment for men with confirmed
    hypogonadism; and
  • InvicorpTM, an injectable combination drug treatment for erectile
    dysfunction, for which Ardana has marketing and manufacturing rights in
    Europe and has been launched in Denmark.



For further information please see www.ardana.co.uk


                      This information is provided by RNS
            The company news service from the London Stock Exchange